research personnel. Information must also be provided on the nature of 
the health surveillance program, if instituted. 
7 
II-A-l-d. Statement on Shipping and Accuracy of MU A . The 
principal investigator must provide a specific brief statement (i) agree- 
ing to abide by the provisions of the NIH Guidelines and the requirements 
of this Supplement concerning shipment and transfer of recombinant DNA 
materials, and (ii) attesting to the accuracy of the information in 
the MUA (see item d in Illustration). 
II-A-l-e. Information Concerning IBC Review . A certification is 
required that the IBC has reviewed the proposed project and found it to 
be in compliance with the NIH Guidelines, this Supplement, and other 
specific NIH instructions. The date of review by the IBC must be 
specified. 
When facilities are proposed, under construction, or in renovation 
at the time the MUA is reviewed, the IBC review must include an assurance 
that recombinant DNA experimentation will not occur until the IBC has 
surveyed the completed facility, found it to be in compliance with the 
Guidelines, and verified that an amended MUA has been submitted to NIH. 
NOTE: Sonne MUAs may have to incorporate a certification as well as 
an assurance if both certified facilities and facilities under construc- 
tion or renovation are involved. 
[ 70 ] 
